HD204
Phase 3Small molecule
HD204 is one of 35 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
HD204
PPrestige Biopharma Limited
Phase 3
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
REGN2810
RegeneronPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bevacizumab1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HD204. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPrestige Biopharma Limited